DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for tenosynovitis — screening already-approved drugs against its 11-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleTenosynovitis maps to a 11-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for tenosynovitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
FTO alpha-ketoglutarate dependent dioxygenase (FTO) — FTO is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3-hydroxypyridin-2-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4IE5 · 1.95 Å · ligand N-[(3-hydroxypyridin-2-yl)carbonyl]glycine (MD6). Experimental structure, not a prediction.
What the evidence adds up to
In 2016, an Italian observational study of 427 rheumatoid arthritis patients in clinical remission found that ultrasound-detected tenosynovitis was common: grey-scale prevalence 52.5% (95% CI 0.48–0.57) and power Doppler prevalence 22.7% (95% CI 0.19–0.27). Only power Doppler tenosynovitis, not synovitis, was significantly associated with patient-reported flare (odds ratio 1.95, 95% CI 1.17–3.26) and with shorter remission duration and morning stiffness. No cross-sectional association was found between tenosynovitis and functional disability measured by HAQ. Radiographic erosions were linked to synovitis but not to tenosynovitis.
A 2001 study of 111 ankle tenograms with at least six months of follow-up reported outcomes after contrast, anaesthetic, and steroid injection into tendon sheaths. For 65 posterior tibial tenograms, 31 patients (48%) had complete or near-complete symptom resolution, 17 (26%) had no relief, and 17 (26%) had initial relief followed by return of pain. For 39 peroneal tenograms, 18 (46%) had complete or near-complete resolution, 10 (26%) had no relief, and 11 (28%) had initial relief then pain return. Two anterior tibial tenograms gave complete relief. No correlation was found between the radiographic degree of tenosynovitis and therapeutic improvement. Complications included one posterior tibial tendon rupture (0.89%) and 14 cases of skin discolouration at the injection site.
A 2025 case report described a 39-year-old vaccinated man with de Quervain’s tenosynovitis whose symptoms recurred during a COVID-19 infection and again during an influenza infection, despite initial successful treatment with corticosteroid injection. The second recurrence required surgical release. The authors hypothesise that viral-induced systemic inflammation may trigger localised recurrence within the tendon sheath, but they note that cytokine analysis and inflammatory markers are needed to test this idea.
What is still missing: prospective trials comparing steroid injection to placebo or surgery for tenosynovitis in non-rheumatoid populations; studies that stratify patients by ultrasound findings or viral exposure history; and funding for mechanistic work linking systemic inflammation to local tendon sheath recurrence.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Lara D. Veeken · 2016 · 54 citations · open access
Ultrasound-detected tenosynovitis independently associates with patient-reported flare in patients with rheumatoid arthritis in clinical remission: results from the observational study STARTER of the Italian Society for Rheumatology
AbstractOBJECTIVES: This study aimed to estimate the prevalence of US-detected tenosynovitis in RA patients in clinical remission and to explore its clinical correlates. METHODS: A total of 427 RA patients in clinical remission were consecutively enrolled from 25 Italian rheumatology centres. Tenosynovitis and synovitis were scored by US grey scale (GS) and power Doppler (PD) semi-quantitative scoring systems at wrist and hand joints. Complete clinical assessment was performed by rheumatologists blinded to the US results. A flare questionnaire was used to assess unstable remission (primary outcome), HAQ for functional disability and radiographic erosions for damage (secondary outcomes). Cross-sectional relationships between the presence of each US finding and outcome variables are presented as odds ratios (ORs) and 95% CIs, both crude and adjusted for pre-specified confounders. RESULTS: The prevalence of tenosynovitis in clinical remission was 52.5% (95% CI 0.48, 0.57) for GS and 22.7% (95% CI 0.19, 0.27) for PD, while the prevalence of synovitis was 71.6% (95% CI 0.67, 0.76) for GS and 42% (95% CI 0.37, 0.47) for PD. Among clinical correlates, PD tenosynovitis associated with lower remission duration and morning stiffness while PD synovitis did not. Only PD tenosynovitis showed a significant association with the flare questionnaire [OR 1.95 (95% CI 1.17, 3.26)]. No cross-sectional associations were found with the HAQ. The presence of radiographic erosions associated with GS and PD synovitis but not with tenosynovitis. CONCLUSIONS: US-detected tenosynovitis is a frequent finding in RA patients in clinical remission and associates with unstable remission.
American Journal of Roentgenology · 2001 · 34 citations
Diagnostic and Therapeutic Ankle Tenography
AbstractOBJECTIVE: The purpose of our study was to evaluate tenography complications and outcomes in a large series. MATERIALS AND METHODS: Of 144 tenograms obtained consecutively from May 5, 1995, to March 17, 1997, 111 were located for at least a 6-month follow-up; 65 were posterior tibial, 39 peroneal, two anterior tibial, three flexor digitorum longus, and two flexor hallucis longus tenograms. Tenography was performed fluoroscopically with contrast material and anesthetic followed by steroid placement into tendon sheaths. RESULTS: Of 65 patients undergoing posterior tibial tenography, 31 (48%) had complete or near-complete symptom resolution; 17 (26%) had no relief. Seventeen patients (26%) had initial relief with the subsequent return of pain to the pretenography level. Of 39 patients undergoing peroneal tenography, 18 (46%) had complete or near-complete symptom resolution; 10 (26%) had no and 11 (28%) had initial relief with subsequent pretenography pain return. Of three patients undergoing flexor digitorum longus tenography, one had complete, one had no, and one had initial relief with complete pretenography pain return. One of two patients who underwent flexor hallucis longus tenography had no relief; the other had initial relief with complete pain return. Two patients who underwent anterior tibial tenography had complete pain relief. We found no correlation between degree of tenosynovitis shown radiographically and therapeutic improvement with anesthetic and steroid injection. Tenography complications included one posterior tibial tendon rupture (0.89%) and 14 patients with skin discoloration at the tendon sheath injection site. CONCLUSION: Forty-seven percent of surgical candidates whose condition was refractory to conservative therapy had complete or near-complete prolonged symptom relief after tenography. In appropriate patients, tenography is excellent therapy for tenosynovitis. Certain precautions make complications rare.
Case Reports in Infectious Diseases · 2025 · 0 citations · open access
De Quervain’s Tenosynovitis Virally Exacerbated by SARS‐CoV‐2 and Influenza Infections: A Case Report
AbstractWe present the case of a fully vaccinated 39-year-old male with no pertinent past medical history who initially presented with De Quervain's tenosynovitis which was successfully treated with a corticosteroid injection. His symptoms recurred during a COVID-19 infection, which was treated with a repeat corticosteroid injection. Symptoms recurred during an influenza infection and were subsequently treated with a first dorsal compartment release. The etiology of De Quervain's tenosynovitis remains unclear. It has classically been categorized as a noninflammatory degenerative process, but recent evidence suggests a possible inflammatory connection. Here, we present a case of recurrent De Quervain's tenosynovitis exacerbated by two distinct viral infections. We hypothesize that viral-induced systemic inflammation led to localized recurrence of inflammation within the tendon sheath. Further studies including cytokine analysis and inflammatory markers are needed to advance this hypothesis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
